Liebenberg N, Joca S, Wegener G. Nitric oxide involvement in the antidepressant-like effect of ketamine in the Flinders sensitive line rat model of depression.
Introduction
A relatively recent and potentially ground-breaking discovery in antidepressant research has been that a single intravenous administration of a sub-anaesthetic dose of ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, elicits a rapid (within a couple of hours) improvement of mood in depressed patients (1) (2) (3) (4) . Preclinical studies have identified a number of molecular mechanisms that appear to underlie the unique antidepressant profile of ketamine (reviewed in (5) ). Briefly, it is thought that by increasing glutamate signalling through α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors relative to NMDA receptors (6) , ketamine activates a cascade of downstream cellular processes, including protein kinase B (Akt), extracellular signal regulated protein kinase (ERK) and the mammalian target of rapamycin (mTOR), hereby leading to a rapid increase in synaptic protein synthesis and synaptogenesis in the frontal cortex (7) .
However, although our understanding of these downstream pathways are ever expanding, the specific signalling mechanisms that are affected further upstream, that is, directly downstream of NMDA receptors following their antagonism by ketamine, remain largely unexplored. A possible mechanism may involve the glutamate (Glu)/ N-methyl-D-aspartate receptor (NMDAR)/NO/cGMP signalling pathway: neuronal nitric oxide synthase (nNOS), the major NO producing enzyme in the brain, is physically coupled to NMDA receptors via postsynaptic density protein 96, and increases NO production in response to the Ca 2+ influx produced by glutamate-mediated NMDA receptor activation (8) . Released NO stimulates soluble guanylyl cyclase, which leads to the synthesis of the second messenger, cGMP.
There are several indications for the involvement of the Glu/NMDAR/NO/cGMP pathway in the pathophysiology of depression as well as in the action of antidepressants. For example, depressed patients exhibit elevated plasma nitrate levels (9), whereas pre-clinical studies have demonstrated antidepressant-like effects following the local or systemic administration of NOS inhibitors (10) (11) (12) (13) (14) (15) (16) . Furthermore, the Glu/NMDAR/NO/cGMP pathway has been shown to be involved in the antidepressantlike activity of a range of different drugs using rodent models (11) (12) (13) (17) (18) (19) (20) (21) (22) . The specific brain area(s) that are involved in these effects remain unclear, but it appears that the hippocampus may play an important role. For instance, the intra-hippocampal injection of an NMDA receptor antagonist (23) or a selective nNOS inhibitor (14, 24) produces antidepressant-like effects, whereas local administration of serotonergic antidepressants reduces hippocampal NOS activity in rats (11) .
A recent study has provided the first evidence suggesting that the glutamate/NMDAR/NO/cGMP pathway may be involved in the antidepressant action of ketamine (20) . This study found that pre-treatment of healthy Wistar rats with the NO precursor, L-arginine, prevented the antidepressant-like effect of ketamine in the forced swim test (FST), and in the same study it was shown that ketamine decreased NOS activity in the hippocampus. Here we further investigated the involvement of NO signalling in the antidepressant action of ketamine by using a wellvalidated genetic rat model of depression, namely the Flinders sensitive line (FSL) rats (reviewed in (25, 26) ). Specifically, we tested whether pretreatment with L-arginine (30 min before ketamine) can prevent the antidepressant-like effect of ketamine in this model of depression, while evaluating changes in total NOS activity [referred to here as constitutional NOS (cNOS) activity] and cGMP levels in the hippocampus and frontal cortex, as a measure of the activation state of the Glu/NMDAR/ NO/cGMP pathway in these regions.
Methods

Animals
Male FSL and Flinders resistant line (FRL), weighing 274.4 ± 7.7 g, were used. Animals were pair-housed in a temperature-and humidity-controlled environment under a 12-h light/dark cycle (lights on at 06:00 a.m.), with ad libitum access to food and water. All animal procedures were carried out under the approval of the Danish National Committee for Ethics in Animal Experimentation (2012-15-2934-00254).
Treatments
Thirty-two FSL rats (eight rats per group) were randomly assigned to the following treatment groups: (1) vehicle (saline), (2) ketamine (15 mg/kg, i.p.), (3) L-arginine (500 mg/kg, i.p.) and (4) L-arginine + ketamine. One group of FRL rats (n = 8) were included to validate the depression-like phenotype of FSL rats, and to investigate baseline differences in NO signalling between the two strains. The L-arginine injections were given 30 min before ketamine, which was administered 1 h before the FST. FSL rats that did not receive either L-arginine or ketamine at a specific time point, as well as all FRL rats, received vehicle injections (saline, i.p.) at these times. The drug doses were based on previous reports using these drugs in rodents (7, 10, 17, 22, 27) . Animals were decapitated 90 min after ketamine or Nitric oxide and ketamine's antidepressant mechanism vehicle injection, and the frontal cortex and hippocampus regions dissected and kept at −80°C for subsequent molecular assays.
Behavioural testing
Open field test. Locomotor activity was assessed individually for each rat in a square open field arena (1 m 2 ) for 5 min directly before the FST, in order to detect possible stimulatory effects of the treatments on locomotor activity, which may induce false positives in the FST. The behaviour of the animals was recorded digitally and the total distance moved (cm) was scored using EthoVision XT video tracking software (version 6.0.324; Noldus Information Technology, Wageningen, The Netherlands).
FST. The FST was carried out as previously described (28) . Briefly, the rats underwent a pre-swim session 24 h before the final test session by placing them into cylinders containing 30 cm of clean tap water at 22°C, for 15 min. This was done to induce a state of behavioural despair (28) . Twenty-four hours later, the rats were again placed in the waterfilled cylinders and subjected to another 5 min swim session during which their behaviour was recorded digitally. The time spent immobile, defined as when a rat makes only the necessary movements to keep its head above the water, was scored by an observer that was blind to the strain and treatment conditions.
cGMP measurement
Hippocampal and frontal cortical cGMP tissue levels were measured using a commercially available low-pH enzyme immunoassay (ELISA) kit (Sigma Aldrich, MO, USA), and by using the acetylated protocol for increased sensitivity. Measurements were corrected for protein concentration by using the BCA Protein Reagent Kit (Thermo Fisher Scientific, Rockford, IL, USA). 
Data analysis and statistics
Differences in between control FSL and FRL rats were analysed for each measurement by using Student's t-tests (GraphPad Prism version 5.00; San Diego CA, USA). Treatment effects in FSL rats were analysed by using one-way analyses of variance (ANOVA) followed by a Newman-Keuls test. Statistical significance was defined as p < 0.05. Group sizes consisted of eight rats per group for all measurements.
Results
Behavioural tests
FST. Vehicle-treated FSL rats displayed an increased immobility in the FST compared with FRL controls (p < 0.0001, Fig. 1a) , thus validating the depression-like Open field test. FSL rats displayed significantly higher locomotor activity compared with FRL controls (p = 0.0033, Fig. 1b) . None of the treatments significantly altered locomotor activity in FSL rats [F(3,28) = 0.864, p = 0.47].
cNOS activity
Ketamine did not affect cNOS activity in FSL rats in the frontal cortex [F(3,26) = 5.89, p = 0.0033], whereas in the hippocampus, ketamine induced a small but significant reduction in cNOS activity [F(3,28) = 14.61, p < 0.001]. L-arginine treatment on its own reduced cNOS activity in the frontal cortex as well as in the hippocampus regions of FSL rats, whereas rats that received both L-arginine and ketamine exhibited reduced cNOS activities in both frontal cortex and hippocampus. We did not observe a significant difference in baseline cNOS activity in the frontal cortex of FSL rats compared with FRL controls (p = 0.54, Fig. 2a) . However, FRL control rats exhibited lower cNOS activity in the hippocampus compared with vehicle-treated FSL rats (p < 0.001, Fig. 2b ). 
Discussion
This study provides behavioural and molecular evidences to suggest the involvement of the Glu/ NMDAR/NO/cGMP pathway in the antidepressant action of the NMDA receptor antagonist, ketamine. Together with a previous study (20) , these are the first direct evidences for such an involvement, although it could have been predicted considering the well-known physiological link between NMDA receptors and NO signalling. In accordance with the study by Zhang et al. (20), we found that a systemic injection of the NO precursor, L-arginine, prevented the behavioural antidepressant-like action of ketamine in the FST (Fig. 1a) , only here in a disease model of depression. This is a particularly interesting finding, since it points to an involvement of the Glu/ NMDAR/NO/cGMP pathway in the antidepressant activity of ketamine. The depression-like phenotype of FSL rats was confirmed in this experiment by exhibiting a significantly higher immobility relative to control FRL rats. We did not detect any differences in locomotor activity induced by the treatments, and any changes in immobility can therefore not be attributed to alterations in locomotion.
On the molecular level, we found that ketamine induced a modest but significant reduction in cNOS activity in the hippocampus, but not in the frontal cortex (Fig. 2) . This is in line with the evidences mentioned in the Introduction section that suggest that the hippocampus is an important site of involvement for the mood-altering function of the Glu/NMDAR/NO/cGMP pathway. Also, the study by Zhang et al. found a reduction in total NOS activity in the hippocampus following treatment with ketamine (20) , although this was the only region investigated. Interestingly, and seemingly in contrast to its inhibiting action on NOS activity, ketamine strongly increased cGMP levels in the frontal cortex as well as the hippocampus. Although L-arginine administration prevented the effects of ketamine in the FST and on cGMP concentration, its action on cNOS activity was somewhat unexpected in that L-arginine reduced cNOS activity in both brain areas. This result may, however, be explained by the metabolic conversion of L-arginine to agmatine, a molecule that is known to inhibit NOS activity (29) . This said, another study using the same dose of L-arginine reported an increase in NO end-products, although this study was carried out in mice (22) . Another possible explanation may be that elevated arginine levels in the brain samples may have competed and interfered with the radioactive arginine used in the NOS assay. The data from our study can therefore not provide direct evidence that L-arginine blocks ketamine's effects specifically by reversing its inhibiting action on NOS activity. Nevertheless, the reversal of the ketamine-induced elevation in cGMP levels in both brain regions by the co-administration of L-arginine (Fig. 3 ) does indicate that NO signalling is involved to some extent in ketamine's antidepressant mechanism.
Considering that ketamine reduced cNOS activity in this study, a concurrent increase in cGMP levels may seem contradictory. However, this result may be explained by considering the intra-and extrasynaptic compartmentalisation of NMDA receptors. Ketamine is an open-channel NMDA receptor blocker, and is therefore theoretically more selective for extrasynaptic NMDA receptors, since these spend longer in the 'open' configuration because of a more tonic activation by extrasynaptic glutamate. Extrasynaptic NMDA receptors are known to induce long-term depression and are linked to neuronal inefficiency mechanisms (30) (31) (32) , and their selective antagonism can be expected to increase neuronal activity. Indeed, it has been shown that systemically injected ketamine induces an acute (within 20 min) increase in extracellular glutamate levels in the frontal cortex of rats (33) , which may be an indication of increased glutamate overflow from synapses due to enhanced neuronal firing. Thus, it may be postulated that the ketamine-induced increase in cGMP levels observed here may have resulted from an increased stimulation of intrasynaptically located NMDA receptors, secondary to enhanced neuronal firing caused by the blockade of extrasynaptic NMDA receptors on glutamatergic neurons. Another plausible explanation is that ketamine may block NMDA receptors on GABA-ergic neurons, leading to decreased GABA outflow and increased glutamatergic firing. In line with this, the involvement of GABA in ketamine's antidepressant action has been demonstrated in a recent rat study (34) .
The observation that L-arginine pre-treatment prevented both the increases in cGMP levels as well as the behavioural antidepressant-like effect of ketamine is strongly indicative of the involvement of elevated cGMP levels in ketamine's antidepressant action. However, whether this underlies the rapid antidepressant action of ketamine remains to be shown, since the behavioural test used in this study (the FST) is not suited for evaluating onset of action. Other, more 'chronic' models of depression, such as chronic mild stress or olfactory bulbectomy may be considered for the future investigation of this hypothesis.
Lastly, we observed reduced cNOS activity in the hippocampus of FRL control rats relative to vehicletreated FSL rats (Fig. 2b) . This result is not all that surprising since a previous report has shown hyperactive NO signalling in the hippocampus of FSL versus FRL rats (35) , and is in agreement with other preclinical studies linking changes in NO signalling in the hippocampus to antidepressant action and depression-like behaviour (14, 23, 24) . This result can thus support the construct validity of FSL rats as a model of depression.
Conclussion
Together with another recent study (20) , we provide here the first behavioural and molecular evidences to indicate the involvement of the NO signalling pathway in the antidepressant mechanism of the rapid-acting antidepressant, ketamine. In particular, it appears that an increase in cGMP in the hippocampus and possibly the frontal cortex may play an integral role in its antidepressant mechanism. These findings contribute to our current knowledge regarding the link between the Glu/NMDAR/NO/cGMP pathway and the antidepressant mechanism of a rapid-acting antidepressant, and may assist future research in the ongoing search for novel faster-acting and more efficient antidepressants.
